Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.58 |
| ▸ | BCR | P11274 | 6/20 | 0.58 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8710179 | 0.86 | MAOB (0.66) | MAOBCYP4F2CYP4A11CALM1NPC1 | |
| SCHEMBL26784208 | 0.85 | ABL1 (0.62) | ABL1ABCB1BCRRXRAMAOB | |
| SCHEMBL77472 | 0.80 | TAAR1 (0.61) | MAOBCYP4F2CYP4A11CALM1SMN1; SMN2 | |
| SCHEMBL919408 | 0.80 | AKR1B1 (0.55) | CYP19A1CALM1AKR1B1 | |
| SCHEMBL15824826 | 0.79 | PTGS2 (0.54) | ABL1ABCB1BCRMAOBCYP19A1 | |
| SCHEMBL2278286 | 0.78 | RXRA (0.53) | ABL1ABCB1BCRRXRARXRB | |
| SCHEMBL31497794 | 0.78 | TAAR1 (0.59) | MAOBCYP4F2CYP4A11CALM1SMN1; SMN2 | |
| SCHEMBL12680470 | 0.77 | MAOB (0.54) | MAOBCALM1SMN1; SMN2 | |
| SCHEMBL26784215 | 0.77 | ABL1 (0.57) | ABL1ABCB1BCRRXRAMAOB | |
| SCHEMBL2044945 | 0.77 | CA2 (0.65) | MAOBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8313669-B2 | Liquid-crystal display | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-11-20 | — | — | US | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| EP-2181174-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2181174-A1 | LIQUID CRYSTAL DISPLAY | Merck Patent GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030322-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110101269-A1 | LIQUID-CRYSTAL DISPLAY | KLK3, LPXN, PSAP | ABL1 670/4885ABCB1 4224/4885BCR 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.